Skip to content

Trial · Observational

Status unknownPhase not statedRegistry data

IVF Outcome in Polycystic Ovary Syndrome Patients

NCTNCT04104958 (opens ClinicalTrials.gov in a new tab)Other idPCOS IVF
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Measures Humanin, does not give it. It appears in an outcome measure.

Overview

Status
Status unknown
Phase
Phase not stated
Enrollment
100 participants (estimated)
Sponsor
Assiut University · Other
Design
Not stated
Countries
Not stated
Start
1 Mar 2020 (estimated)
Primary completion
1 Dec 2020 (estimated)
Completion
15 Feb 2021 (estimated)
First posted
26 Sept 2019
Last update posted
10 Jan 2020
Conditions
Polycystic Ovary Syndrome

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202020212022
  1. Ph –

    IVF Outcome in Polycystic Ovary Syndrome Patients

    NCT04104958

    est. 1 Mar 2020 to est. 15 Feb 2021

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

1. To investigate the circulating concentrations of phoenixin and their associations with BMI, the concentrations of sex hormones including (LH), (FSH), (E2), (P4), (TT) and steroid hormones enzyme in PCOS patients. 2. To detect the expression PNX and humanin in women with or without PCOS and to elucidate possible correlations with ovarian reserve and clinical outcomes after IVF-ICSI. 3. To investigate relationship between PNX, humanin expression and PI3K/AKT/mTOR and autophagy pathway as a major signaling mechanism in PCOS for targeting new prognostic and therapeutic markers. 4. The study investigates the correlation between oocyte maturity, fertilization, recent biomarkers and a variety of hormonal parameters in follicular fluid.

Interventions

  • qRTPCR (mRNA level).Genetic

Arms2

  • Other

    Group 1

    Group 1 (n=50): women (age 20-40year) with PCOS who are diagnosed according to the criteria of the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003), which require two of the following 3 manifestations: 1. oligo- or anovulation, 2. clinical and/or biochemical signs of hyperandrogenism (\> 2.08 nmol/l), 3. polycystic ovaries on ultrasound examination (the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume \> 10 cm)

  • Other

    Group 2

    Group 2 (n=50): women (age 20-40 year) with male factor infertility.

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Detect difference in expression of phoenixin and humanin in PCOS

    Time frame · Baseline

    Registry description

    Detect difference in expression of phoenixin and humanin markers in follicular fluid and their role in pathogenesis of PCOS.

  2. Assess the link between phoenixin and humanin through the PI3/AKT/mTOR

    Time frame · Baseline

    Registry description

    Assess the link between phoenixin and humanin through the PI3/AKT/mTOR and autophagy signalling pathway that may be considered as a future therapeutic target in PCOS patients to improve IVF outcome.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

PubMed tag: none · 2019

9 results

Follicular fluid humanin concentration is related to ovarian reserve markers and clinical pregnancy after IVF-ICSI: a pilot study.

Rao et al. 2019Reproductive biomedicine onlinecited by 25

PMID 30503199DOI 10.1016/j.rbmo.2018.11.002PUB-30503199

Full text at the publisher9 results
Publisher pageSee results (9)

Eligibility

Who could join, as posted.

Sex
Female
Age
from 20 Years up to 40 Years
Healthy volunteers
Not stated
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * • The diagnosis included donors, male factor infertility and PCOS women. * Age ranging from 20 to 40 years Exclusion Criteria: * • There were no other etiologies for the PCOS cases, such as congenital adrenal hyperplasia, 21-hydroxylase deficiency, androgen-secreting tumors, Cushing's syndrome, thyroid disease, and hyperprolactinemia. * Patients with endometriosis. * Patients with history of coronary artery disease, hypertension, liver cirrhosis or hematologic disorders.

PepBank is a research reference. Talk to a doctor before you use any peptide.